Owkin
Owkin Inks Deal to Offer Its Colorectal Cancer Test Through Proscia's Platform
The firms said that Owkin's MSIntuit CRC v2 screening test for microsatellite instability will be available through the Proscia Concentriq software platform.
Owkin, MSD Collaborate on Digital Pathology Cancer Diagnostics
Owkin and MSD — known as Merck in the US and Canada — will develop and commercialize microsatellite instability high diagnostics in the EU for four types of cancer.
Owkin-led Machine Learning Study IDs Possible Cancer Treatment Biomarkers Using Federated Model
Premium
AI firm Owkin used distributed on-site analysis of whole-slide images to identify triple-negative breast cancer patients who might respond to neoadjuvant therapy.